<DOC>
	<DOC>NCT00422214</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (SeroquelÂ®) in the treatment of patients with Acute Bipolar Depression for 8 weeks. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Phase III/Seroquel SR Bipolar Depression Monotherapy - US</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Affective Disorders, Psychotic</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision of written informed consent Documented diagnosis of Bipolar 1 disorder or Bipolar 11 disorder Outpatient status at enrollment Patients with &gt;8 mood episodes during the past 12 years Use of prohibited medications Substance or alcohol abuse or dependence Current suicide risk or suicide attempt within last 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Bipolar Depression,</keyword>
	<keyword>Manic Depression</keyword>
	<keyword>Seroquel</keyword>
	<keyword>Seroquel SR</keyword>
	<keyword>quetiapine fumarate</keyword>
</DOC>